| Literature DB >> 33785855 |
Selda Hançerli Törün1, Özge Kaba2, Nurhayat Yakut3, Eda Kepenekli Kadayıfçı3, Manolya Kara2, Mehpare Sarı Yanartaş2, Ayper Somer2, Burcu Bursal Duramaz4, Özden Türel4, Nazan Dalgıç5, Emel Ekşi Alp5, Enes Salı6, Deniz Çakır6, Pınar Önal7, Haluk Çokuğraş7, Fatma Deniz Aygün8, Adem Karbuz9, Mustafa Önel10, Sevim Meşe10, Ali Ağaçfidan10.
Abstract
The frequency of bacterial factors causing central nervous system infections has decreased as a result of the development of our national immunization program. In this study, it is aimed to obtain the data of our local surveillance by defining the viral etiology in cases diagnosed with meningoencephalitis for 1 year. Previously healhty 186 children, who applied with findings suggesting viral meningoencephalitis to 8 different tertiary health centers between August 2018 and August 2019, in Istanbul, were included. The cerebrospinal fluid (CSF) sample was evaluated by polymerase chain reaction. The M:F ratio was 1.24 in the patient group, whose age ranged from 1 to 216 months (mean 40.2 ± 48.7). Viral factor was detected in 26.8%. Enterovirus was the most common agent (24%) and followed by Adenovirus (22%) and HHV type 6 (22%). In the rest of the samples revealed HHV type 7 (10%), EBV (6%), CMV (6%), HSV type 1 (6%), Parvovirus (4%) and VZV (2%). The most common symptoms were fever (79%) and convulsions (45.7%). Antibiotherapy and antiviral therapy was started 48.6% and 4% respectively. Mortality and sequela rate resulted 0.53% and 3.7%, respectively. This highlights the importance of monitoring trends in encephalitis in Turkey with aview to improving pathogen diagnosis for encephalitis and rapidly identifying novel emerging encephalitis-causing pathogens that demand public health action especially in national immunisation programme.Entities:
Year: 2021 PMID: 33785855 PMCID: PMC8010096 DOI: 10.1038/s41598-021-86687-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Distribution of participants by age group and gender.
Figure 2Application seasons of patients who are positive as a result of viral panel. HHV Human Herpes Virus, CMV Cytomegalovirus, HSV Herpes Simplex Virus, EBV Ebstein Barr Virus, VZV Varicella Zoster Virus.
Distribution of age, gender and clinical presentations according to viral panel results.
| Enterovirus (n = 12) | Adenovirus (n = 11) | HHV type 6 (n = 11) | HHV type 7 (n = 5) | EBV (n = 3) | HSV type 1 (n = 3) | CMV (n = 3) | Negative (n = 136) | ||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SS | 35.22 ± 41.47 | 36.54 ± 49.71 | 23.09 ± 37.36 | 73 ± 43.35 | 62 ± 64.81 | 15.66 ± 11.89 | 4.5 ± 2.12 | 42.16 ± 49.12 | |
| M:F | 1:1 | 3:8 | 9:2 | 2:3 | 2:1 | 1:2 | 1:2 | 19:15 | |
| Fever | 10 | 7 | 11 | 3 | 3 | 2 | 2 | 108 | |
| Convulsion | 1 | 6 | 5 | 1 | 1 | 3 | 3 | 62 | |
| Diarrhea | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 19 | |
| Rash | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 6 | |
| Loss ofconsciousness | 4 | 3 | 1 | 2 | 1 | 1 | 0 | 39 | |
| Ataxi | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | |
| Headhache | 3 | 0 | 1 | 2 | 0 | 0 | 0 | 6 | |
| Vomiting | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | |
| Cough | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | |
HHV Human Herpes Virus, CMV Cytomegalovirus, HSV Herpes Simplex Virus, EBV Ebstein Barr Virus.
Distribution of C-reactive protein and CSF laboratory findings and Evaluation of imaging results.
| Enterovirus (n = 12) | Adenovirus (n = 11) | HHV type6 (n = 11) | HHV type7 (n = 5) | EBV (n = 3) | HSV type 1 (n = 3) | CMV (n = 3) | Negative (n = 136) | |
|---|---|---|---|---|---|---|---|---|
| C reactive protein positivity | 83.3% (n = 10) | 54.5% (n = 6) | 45.5% (n = 5) | 80% (n = 4) | 66.6% (n = 2) | 33.3% (n = 1) | 33.3% (n = 1) | 55.8% (n = 76) |
| Anormal BOS WBC count | 83.3% (n = 10) | 27.2% (n = 3) | 18.1% (n = 2) | 80% (n = 4) | 66.6% (n = 2) | 0% (n = 0) | 66.6% (n = 2) | 27.2% (n = 37) |
| Iıncreased CSF protein by age | 33.3% (n = 4) | 27.2% (n = 3) | 36.3% (n = 4) | 60% (n = 3) | 66.6% (n = 2) | 66.6% (n = 2) | 0% (n = 0) | 26.4% (n = 36) |
| CT | 2 | 3 | 6 | 1 | 1 | 0 | 3 | 68 |
| Normal | 2 | 3 | 6 | 1 | 1 | 0 | 3 | 68 |
| Anormal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MRI | 8 | 7 | 6 | 4 | 2 | 3 | 2 | 66 |
| Normal | 7 | 6 | 6 | 2 | 0 | 2 | 2 | 61 |
| Anormal | 1 | 1 | 0 | 2 | 2 | 1 | 0 | 5 |
| Transfontanel USG | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Normal | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Anormal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EEG | 1 | 3 | 1 | 0 | 0 | 1 | 2 | 20 |
| Normal | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 6 |
| Anormal | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 14 |
HHV Human Herpes Virus, CMV Cytomegalovirus, HSV Herpes Simplex Virus, EBV Ebstein Barr Virus, CT Computed tomograpy, MRI Magnetic resonance imagining, USG Ultrasonograpy, EEG:Electroencephalograpy.